The prevalence of hepatic and thyroid toxicity associated with imatinib treatment of chronic myeloid leukaemia: a systematic review
ConclusionHigh frequency of mild and severe hepatotoxicity, associated with imatinib in CML patients, was reported in the published literature. Low numbers of mild and manageable thyroid toxicity events were reported.
Source: International Journal of Clinical Pharmacy - Category: Drugs & Pharmacology Source Type: research
More News: Chronic Leukemia | Chronic Myeloid Leukaemia | Clinical Trials | Databases & Libraries | Drugs & Pharmacology | Gleevec | Leukemia | Liver | Liver Transplant | Science | Study | Thyroid | Toxicology | Transplants | Urology & Nephrology